Literature DB >> 1928357

Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome.

S Idell1, K B Koenig, D S Fair, T R Martin, J McLarty, R J Maunder.   

Abstract

We studied the changes of coagulation and fibrinolysis in bronchoalveolar lavage (BAL) and plasma obtained serially at intervals after the onset of adult respiratory distress syndrome (ARDS). BAL procoagulant activity was increased at 3 days and tended to decrease thereafter. Tissue factor associated with factor VII was the major BAL procoagulant. Fibrinopeptide A was increased, indicating increased thrombin-mediated conversion of fibrinogen to fibrin. Fibrinolytic activity was usually undetectable in BAL at 3 days post-ARDS and remained depressed for up to 14 days despite unchanged concentrations of urokinase and variably detectable tissue plasminogen activator. Depressed fibrinolytic activity was associated with increased antiplasmin activity and plasminogen activator inhibitor 1 (PAI-1) while PAI-2 concentrations approximated those of control samples and did not change during evolving ARDS. Evidence of systemic coagulopathy and increased systemic fibrin degradation were commonly found in serial ARDS plasma samples, consistent with accelerated vascular and/or extravascular fibrin deposition in these patients. The data indicate that intra-alveolar as well as systemic derangements of fibrin turnover are common features of evolving ARDS. Concurrent local abnormalities of both coagulation and fibrinolytic pathways favor persistence of alveolar fibrin for up to 14 days after clinical recognition of ARDS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928357     DOI: 10.1152/ajplung.1991.261.4.L240

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  50 in total

1.  Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury.

Authors:  Torry A Tucker; Ann Jeffers; Alexia Alvarez; Shuzi Owens; Kathleen Koenig; Brandon Quaid; Andrey A Komissarov; Galina Florova; Hema Kothari; Usha Pendurthi; L Vijaya Mohan Rao; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

2.  Feasibility of tissue plasminogen activator formulated for pulmonary delivery.

Authors:  John S Dunn; Rajiv Nayar; Jackie Campos; Brooks M Hybertson; Yue Zhou; Mark Cornell Manning; John E Repine; Kathleen A Stringer
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

3.  Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury.

Authors:  Marcus J Schultz; Marcel Levi
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

4.  Development of animal models for the acute respiratory distress syndrome.

Authors:  Julie A Bastarache; Timothy S Blackwell
Journal:  Dis Model Mech       Date:  2009 May-Jun       Impact factor: 5.758

5.  Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation.

Authors:  Heidi R Flori; Lorraine B Ware; Meredith Milet; Michael A Matthay
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

Review 6.  Biomarkers in acute lung injury.

Authors:  Maneesh Bhargava; Chris H Wendt
Journal:  Transl Res       Date:  2012-02-07       Impact factor: 7.012

7.  Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice.

Authors:  Taher Nassar; Serge Yarovoi; Rami Abu Fanne; Otailah Waked; Timothy C Allen; Steven Idell; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-26       Impact factor: 6.914

8.  Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia.

Authors:  P J Simpson-Haidaris; M A Courtney; T W Wright; R Goss; A Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Novel aspects of urokinase function in the injured lung: role of α2-macroglobulin.

Authors:  Andrey A Komissarov; Dorota Stankowska; Agnieszka Krupa; Rafal Fudala; Galina Florova; Jon Florence; Marek Fol; Timothy C Allen; Steven Idell; Michael A Matthay; Anna K Kurdowska
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-10-12       Impact factor: 5.464

10.  Early elevations in B-type natriuretic peptide levels are associated with poor clinical outcomes in pediatric acute lung injury.

Authors:  Bhupinder Reel; Peter E Oishi; Jong-Hau Hsu; Ginny Gildengorin; Michael A Matthay; Jeffrey R Fineman; Heidi Flori
Journal:  Pediatr Pulmonol       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.